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Abstract
Clozapine is thought to induce obsessive compulsive symptoms (OCS) in schizophrenic patients. However, because
OCS are often comorbid with schizophrenia regardless of clozapine treatment, it remains unclear whether clozapine
can generate OCS de novo. Thus, it has been difficult to establish a causal link between clozapine and OCS in
human studies. To address this question, we asked whether chronic treatment with clozapine can induce obsessive
compulsive disorder (OCD)-like behavior in mice. We injected mice with long-term continuous release pellets
embedded with clozapine four times at 60-day intervals and then monitored the mice for signs of OCD-like
behavior up to 40 wk. of age. We found clozapine increases grooming behavior as early as 30 wk. of age. We also
investigated the effect clozapine on grooming behavior in Sapap3 knockout (KO) mice, which are a well-known
animal model of OCD. In Sapap3 heterozygous KO mice, clozapine increases grooming behavior much earlier than
in wild-type mice, suggesting a clozapine-OCD gene interaction. Fluoxetine, which is often used in the treatment of
OCS and OCD, reduced the grooming behavior induced by clozapine. These data demonstrate that chronic
clozapine treatment can generate OCD-like behavior in mice and support the hypothesis that clozapine produces
de novo OCS regardless of schizophrenia status.
Antiserotonergic second generations antipsychotics (SGA)
like clozapine, risperidone, and olanzapine are widely used
in the treatment of schizophrenia. In contrast to other
SGA that primarily work on dopamine receptors, they
have pronounced antiserotonergic properties [1]. A series
of clinical reports have suggested that the antiserotonergic
SGA may also increase the occurrence of OCS in patients
with schizophrenia [2–4]. But because schizophrenia and
OCS are often comorbid, this effect remains controversial.
Moreover, even if the antiserotonergic SGA do promote
OCS, it is difficult to tell whether this is de novo OCS or
simply an unmasking or exacerbation of pre-existing OCS.
There are several lines of indirect evidence that support a
causal relationship between antiserotonergic SGA and
OCS in schizophrenic patients [4]. First, the prevalence of
OCS increased after market approval of the first SGA [4].
Second, OCS are more prevalent in schizophrenic patients
treated with antiserotonergic SGAs [5, 6]. Third, OCS se-
verity is positively correlated with antiserotonergic SGA
treatment duration and dose size [7]. Although these lines
of evidence strongly suggest a link, more prospective co-
hort studies and studies using disease-relevant animal
models are warranted to fully address this question.
Here, we used normal mice (B6J) to determine
whether clozapine can induce de novo OCD-like symp-
toms. Clozapine is the antiserotonergic SGA most com-
monly associated with OCS in schizophrenia. Because
the onset time of OCS in schizophrenic patients treated
with clozapine is 1 to 96 months (median 19.5 months)
[6], we decided to use specially designed clozapine pel-
lets that slowly and continuously release clozapine for
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60 days. We treated mice (B6J) with clozapine for 240
days by implanting the first clozapine pellet at 12 wk. of
age with follow-up injections at 60-day intervals (Fig. 1a,
see Additional file 1 for the detailed methods). When we
measured blood concentration of clozapine 10 days after
injection, we found evidence of sustained maintenance
of plasma clozapine concentrations (see Additional file 2:
Figure S1A). In mice at 15, 20, 30, and 40 wk. of age, we
recorded 2 h of grooming behaviors using a video cam-
era. Two independent experimenters then manually
scored grooming duration and bout number. We found
clozapine increases grooming time in wild-type mice
Fig. 1 Clozapine-treated mice showed over grooming behavior. a Schematic diagram of experimental procedure. Wild-type and Sapap3+/− adult
mice were administered with either clozapine or placebo for 28 wks, starting from age of 12 wk. b Clozapine-treated wild-type mice showed
increased repetitive grooming behavior. Mice were injected with clozapine or placebo pellets at the age of 12 wk. with 60-day interval pellet
injection. Mice behavior was recorded for 2 h and analyzed at the age of 15, 20, 30, and 40 wk. (Two-way RM ANOVA, main effect of treatment;
F(1,16) = 9.161, p = 0.008, main effect of time; F(3,48) = 5.525, p = 0.002, treatment x time interaction; F(3,48) = 2.981, p = 0.04, ** p < 0.01) (left).
Grooming lasted more than 3 s was counted as a bout (Two-way RM ANOVA, main effect of treatment; F(1,16) = 6.073, p = 0.025, main effect of
time; F(3,48) = 3.491, p = 0.023, treatment x time interaction; F(3,48) = 2.674, p = 0.058, * p < 0.05) (right). c Clozapine-treated Sapap3+/− mice
showed increased repetitive grooming behavior earlier than clozapine-treated wild-type mice. Sapap3+/− mice were injected with clozapine or
placebo pellets at the age of 12 wk. with 60-day interval pellet injection. Mice behavior was recorded for 2 h and analyzed at the age of 12, 15,
20, 30 and 40 wk. (Two-way RM ANOVA, main effect of treatment; F(1,12) = 16.99, p = 0.01, main effect of time; F(3,36) = 10.12, p < 0.001, treatment
x time interaction; F(3,36) = 3.348, p = 0.03, * p < 0.05, ** p < 0.01) (left). Numbers of grooming bouts were counted from 2 h video-recording of
grooming behavior. Grooming bouts were increased in Sapap3+/− mice after 18 wk. of clozapine treatment (Two-way RM ANOVA, main effect of
treatment; F(1,12) = 14.16, p = 0.003, main effect of time; F(3,36) = 11.17, p < 0.001, treatment x time interaction; F(3,36) = 4.095, p = 0.013, ** p <
0.01) (right). d Fluoxetine treatment ameliorated overgrooming behavior in clozapine-treated wild-type mice (Two-way ANOVA, main effect of
fluoxetine treatment; F(1,6) = 21.75, p = 0.003, main effect of clozapine treatment; F(1,6) = 9.27, p = 0.023, fluoxetine treatment x clozapine
treatment interaction; F(1,6) = 7.071, p = 0.038, * p < 0.05, *** p < 0.001) n = 4 per group. All data are presented as means ± SEM
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beginning at 30 wk. of age (18 wk. after 1st clozapine
pellet injection) (Fig. 1b, left). We also found mice
treated with clozapine pellets for 40 wks engage in more
grooming bouts (Fig. 1b, right). We did not see any
change in weight between clozapine- and placebo-
treated mice (see Additional file 2: Figure S1B). In hu-
man studies, genetic interactions of SAPAP3 and
SLC1A1 gene variants are predictive of antiserotonergic
SGA-induced OC symptoms [8]. The homozygous dele-
tion of Sapap3 in mice induces grooming behavior that
is severe enough to develop facial and neck skin le-
sions [9]. Thus, we also tested the effect of clozapine
on OCD-like behavior in Sapap3 knockout mice. We
started to observe the development of skin lesions
from 20 wk. in homozygous mice and this reached
100% penetration by the age of 40–60 wk. Clozapine
does not accelerate the development of skin lesions in
these Sapap3 homozygous KO mice, probably because
the grooming behavior is already so severe (see Add-
itional file 2: Figure S1C). Sapap3 heterozygous KO
mice, in contrast, do not show increased grooming
behavior or skin lesions [9]. Interestingly, we found
clozapine induces grooming behavior in Sapap3 het-
erozygous KO mice earlier than in wild-type mice
(Fig. 1c). We next tested whether fluoxetine, a select-
ive serotonin reuptake inhibitor, can reduce the
grooming behavior induced by chronic clozapine
treatment. As shown in Fig. 1d, we observed that 10
days of daily intraperitoneal fluoxetine injections into
mice administered clozapine for 30 wks significantly
reduces their grooming time. This suggests 5-HT sig-
naling is involved in the pathogenesis of clozapine-
induced OCS and that OCD-like behavior in mice re-
sponds to the therapeutic agents typically used in
humans.
In this study, we demonstrated for the first time
that chronic clozapine administration can induce
OCD-like behavior in mice. We provide new data on
the long-standing question of whether clozapine in-
duces de novo OCS even in normal conditions. There
are several reasons this mouse model is useful for the
study of clozapine-induced OCS. First, as in humans
[6], significant time is required for the induction of
OCD-like behavior after clozapine administration in
mice. Second, this model meets all the criteria of val-
idity for animal models of psychiatric disorders [10];
the mouse model shows OCD-like behavior (face val-
idity), has clozapine as an inducer (construct validity),
and responds to fluoxetine (predictive validity). Lastly,
we confirmed in Sapap3 KO mice a clear interaction
between clozapine and a gene linked to clozapine-
induced OCS in humans [8].
While clozapine is the only antipsychotic agent indi-
cated for treatment-resistant schizophrenia [1], the
occurrence of OCS after initiation of clozapine treat-
ment is associated with additional functional impairment
and poor prognosis of the disease [4]. This animal model
will provide a new opportunity for researchers trying to
develop effective antipsychotics that do not promote
OCS as a side effect. This model will also make it easier
to study the molecular and circuit mechanisms contrib-
uting to OCS from a translational perspective. The
therapeutic effect of fluoxetine we observed suggests the
involvement of 5-HT receptors (5-HT1A, 5-HT2A, and 5-
HT2C), which are thought to be targets of clozapine [1].
The association of SLC1A1 polymorphism with symp-
tom occurrence in human also hints at a potential role
for glutamate neurotransmission [11]. It seems that the
effects of glutamate-related genes on clozapine-induced
OCS represent a genetic predisposition (or susceptibility)
rather than playing a causative role. Fluoxetine also in-
hibits compulsive grooming behavior of Sapap3 homo-
zygous KO mice [9], but only when administered over a
long period of time. This suggests that acute changes in
serotonin levels do not directly suppress compulsive be-
haviors. Instead, selective serotonin uptake inhibitors
may alter clozapine-induced derangement in OCD-
related neural substrates like the cortico-striato-
thalamo-cortical circuit [12, 13]. The relative importance
and contribution of each of these remains unclear. Fur-
ther study of the actions of clozapine in this new mouse
model will improve our understanding of the pathogen-
esis of OCS and accelerate the development of antipsy-
chotics that lack OCS-inducing side effects.
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Additional file 1. Raw data of the tested parameters in wild-type.
Additional file 2: Figure S1. A Plasma clozapine concentration 10 days
after clozapine pellet injection. Placebo-injected age-matched mice were
used as controls (Student t test, ** p < 0.01). n = 4 per group. B Body
weight change of clozapine- or placebo-treated mice in wild-type and
Sapap3+/− mice. There was no significant difference between clozapine-
and placebo-treated mice. n = 5–6 per group C Survival curve of skin le-
sion development in Sapap3-/- mice (left). Sapap3-/- mice have neck and
facial skin lesions (white arrows). n = 7–12 per group. All data are pre-
sented as means ± SEM.
Additional file 3. Sapap3-/- mice.
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